Tyr338
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr338  -  NPM-ALK (human)

Site Information
FGMARDIyRAsyyRK   GenPept
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27275110
Available spectra:  2 CST
Associated spectra:  4 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 7 , 8 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 8 ) , mutation of modification site ( 7 , 8 ) , phospho-antibody ( 1 ) , western blotting ( 1 , 7 , 8 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung cancer ( 2 , 3 , 4 , 5 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 5 ) , non-small cell large cell lung carcinoma ( 2 ) , lymphoma ( 7 ) , T cell lymphoma ( 7 )
Relevant cell line - cell type - tissue:
293GP (epithelial) ( 6 , 7 , 8 ) , HCC78 (pulmonary) ( 2 ) , HEK293T (epithelial) ( 1 ) , Karpas-299 (T lymphocyte) ( 7 ) , lung ( 2 ) , NCI-H1781 (pulmonary) ( 2 ) , NCI-H2228 (pulmonary) ( 2 , 3 , 5 ) , NCI-H3122 (pulmonary) ( 2 , 4 ) , NCI-H661 (pulmonary) ( 2 )

Upstream Regulation
Putative upstream phosphatases:
SHP-1 (human) ( 7 )

Downstream Regulation
Effects of modification on NPM-ALK:
enzymatic activity, induced ( 8 )

References 

1

Lovisa F, et al. (2015) ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors. PLoS One 10, e0121378
25874976   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K (2013) CST Curation Set: 18458; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

4

Rikova K (2013) CST Curation Set: 18450; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

5

Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

6

Wang P, et al. (2011) Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. Carcinogenesis 32, 146-53
21045017   Curated Info

7

Hegazy SA, et al. (2010) The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. J Biol Chem 285, 19813-20
20424160   Curated Info

8

Wang P, et al. (2010) Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry. J Biol Chem 285, 95-103
19887368   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.